Long‐term, real world, efficacy of biologics for psoriasis: a single centre's experience

Abstract

Biologic therapies have revolutionised the management of moderate to severe chronic plaque psoriasis and have been life‐transforming for many patients. The first biologic to be licensed for psoriasis in the UK was efalizumab in 2004 and there are now nine licensed by the European Medicines Agency for the indication of moderate‐severe disease. A key determinant in choosing a biologic for an individual patient is the likelihood of long‐term efficacy and for some there is compelling evidence that monotherapy can result in long‐term disease control.

This article is protected by copyright. All rights reserved.

http://bit.ly/2BvassX